PFIZER INC Sales Revenue, Goods, Net (Deprecated 2018-01-31)
PFIZER INC (PFE) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $12.91 billion for the 3-month period ending 2018-04-01, per its 10-Q filed 2018-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-10
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-04-01 was $12.91B, a 0.99% increase year-over-year.
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $13.70B, a 0.55% increase year-over-year.
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-10-01 was $13.17B, a 0.94% increase year-over-year.
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-07-02 was $12.90B, a 1.91% decline year-over-year.
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $52.55B, a 0.53% decline from fiscal 2016.
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $52.82B, a 8.13% increase from fiscal 2015.
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $48.85B, a 1.52% decline from fiscal 2014.
- PFIZER INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $49.60B, a 3.84% decline from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-04-01 | $12.91B 10-Q · filed 2018-05-10 | $26.61B derived: sum of 2 quarters · filed 2018-05-10 | $39.78B derived: sum of 3 quarters · filed 2018-05-10 | $52.67B derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $13.70B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $26.87B derived: sum of 2 quarters · filed 2018-02-22 | $39.77B derived: sum of 3 quarters · filed 2018-02-22 | $52.55B 10-K · filed 2018-02-22 |
| 2017-10-01 | $13.17B 10-Q · filed 2017-11-09 | $26.06B derived: sum of 2 quarters · filed 2017-11-09 | $38.84B 10-Q · filed 2017-11-09 | $52.47B derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-07-02 | $12.90B 10-Q · filed 2017-08-10 | $25.68B 10-Q · filed 2017-08-10 | $39.30B derived: sum of 3 quarters · filed 2018-05-10 | $52.35B derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-04-02 | $12.78B 10-Q · filed 2018-05-10 | $26.41B derived: sum of 2 quarters · filed 2018-05-10 | $39.45B derived: sum of 3 quarters · filed 2018-05-10 | $52.60B derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $13.63B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $26.67B derived: sum of 2 quarters · filed 2018-02-22 | $39.82B derived: sum of 3 quarters · filed 2018-02-22 | $52.82B 10-K · filed 2018-02-22 |
| 2016-10-02 | $13.04B 10-Q · filed 2017-11-09 | $26.19B derived: sum of 2 quarters · filed 2017-11-09 | $39.20B 10-Q · filed 2017-11-09 | $53.24B derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-07-03 | $13.15B 10-Q · filed 2017-08-10 | $26.15B 10-Q · filed 2017-08-10 | $40.20B derived: sum of 3 quarters · filed 2018-02-22 | $52.29B derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-04-03 | $13.01B 10-Q · filed 2017-05-11 | $27.05B derived: sum of 2 quarters · filed 2018-02-22 | $39.14B derived: sum of 3 quarters · filed 2018-02-22 | $50.99B derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | $14.05B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $26.13B derived: sum of 2 quarters · filed 2018-02-22 | $37.99B derived: sum of 3 quarters · filed 2018-02-22 | $48.85B 10-K · filed 2018-02-22 |
| 2015-09-27 | $12.09B 10-Q · filed 2016-11-10 | $23.94B derived: sum of 2 quarters · filed 2016-11-10 | $34.80B 10-Q · filed 2016-11-10 | $47.92B derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-28 | $11.85B 10-Q · filed 2016-08-11 | $22.72B 10-Q · filed 2016-08-11 | $35.84B derived: sum of 3 quarters · filed 2017-02-23 | $48.20B derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-29 | $10.86B 10-Q · filed 2016-05-12 | $23.98B derived: sum of 2 quarters · filed 2017-02-23 | $36.34B derived: sum of 3 quarters · filed 2017-02-23 | $49.12B derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $13.12B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $25.48B derived: sum of 2 quarters · filed 2017-02-23 | $38.25B derived: sum of 3 quarters · filed 2017-02-23 | $49.60B 10-K · filed 2017-02-23 |
| 2014-09-28 | $12.36B 10-Q · filed 2015-11-05 | $25.13B derived: sum of 2 quarters · filed 2015-11-05 | $36.49B 10-Q · filed 2015-11-05 | $50.05B derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-29 | $12.77B 10-Q · filed 2015-08-06 | $24.13B 10-Q · filed 2015-08-06 | $37.68B derived: sum of 3 quarters · filed 2016-02-29 | $50.33B derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-30 | $11.35B 10-Q · filed 2015-05-07 | $24.91B derived: sum of 2 quarters · filed 2016-02-29 | $37.55B derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $13.56B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $26.20B derived: sum of 2 quarters · filed 2016-02-29 | $51.58B 10-K · filed 2016-02-29 | |
| 2013-09-29 | $12.64B 10-Q · filed 2014-11-06 | $38.03B 10-Q · filed 2014-11-06 | ||
| 2012-12-31 | $54.66B 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |